+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Liver Cirrhosis - Epidemiology Forecast - 2034

  • PDF Icon

    Report

  • 112 Pages
  • December 2024
  • Region: Global
  • DelveInsight
  • ID: 5524901
UP TO OFF until Dec 31st 2024

Key Highlights

  • The analyst suggests that within the 7MM, there are approximately 3.4 million diagnosed prevalent cases of liver cirrhosis. Notably, the United States contributes approximately 60% of these cases, indicating a significant burden within the country compared to other nations in the 7MM.
  • Liver cirrhosis cases are anticipated to increase due to factors like rising obesity rates and alcohol consumption. The absence of approved drugs highlights a critical gap in treatment options, underscoring the urgent need for effective pharmaceutical interventions in managing this debilitating condition.
  • EU4 and the UK accounted for 24% of the total diagnosed prevalent cases of liver cirrhosis in the 7MM, which is anticipated to show a rise soon.
  • As per the model, the etiology-specific diagnosed prevalent cases of liver cirrhosis were categorized into NASH, HCV, HBV, ALD, and PBC. The highest cases of cirrhosis were for ALD, with approximately 1 million cases, while the lowest cases were of PBC in 2022 among the 7MM countries.
The “Liver Cirrhosis - Epidemiology - 2034” report delivers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2020-2034

Disease Understanding and Diagnostic Algorithm

Liver Cirrhosis Overview

Cirrhosis is the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, leading to portal hypertension and end-stage liver disease. In this late-stage liver disease, the healthy liver tissue is replaced with scar tissue, and the liver is permanently damaged, and scar tissue keeps the liver from working properly. Cirrhosis has many signs and symptoms, such as fatigue and severe itchy skin, and they may not appear until the liver is badly damaged. Causes include alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B.

Liver Cirrhosis Diagnosis

The diagnosis of cirrhosis is usually based on the presence of a risk factor for cirrhosis, such as alcohol use or obesity, and is confirmed by physical examination, blood tests, and imaging. The doctor will ask about the person’s medical history and symptoms and perform a thorough physical examination to observe for clinical signs of the disease. The Child-Pugh scoring system (the Child-Pugh-Turcotte score) was designed to predict mortality in cirrhosis patients.

Organizations like the European Association for the Study of the Liver (EASL), Japanese Society of Gastroenterology (JSGE), American Association for the Study of Liver Diseases (AASLD), and others have published criteria for diagnosing liver cirrhosis.

Liver Cirrhosis Epidemiology

As the market is derived using the patient-based model, the Liver Cirrhosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Liver Cirrhosis, and Etiology-specific diagnosed prevalent cases of Liver Cirrhosis, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per estimations, the total diagnosed prevalent cases of Liver Cirrhosis in the 7MM comprised approximately 3.4 million cases in 2022 and are projected to increase during the forecast period.
  • The US showed the highest diagnosed prevalent population of liver cirrhosis compared to the other 7MM countries, with nearly 2 million cases in 2022. As per estimates, the country alone accounts for nearly 61% of total diagnosed prevalent cases, for liver cirrhosis in the 7MM, followed by Japan, contributing 15% of all the liver cirrhosis cases.
  • The etiology-specific distribution of diagnosed prevalent cases of liver cirrhosis showed NASH, HCV, HVB, ALD, and PBC comprised 28%, 27%, 11%, 33%, and 2% cases, respectively in the 7MM in 2022.
  • EU4 and the UK accounted for around 0.8 million diagnosed prevalent cases of liver in 2022. Of these cases, Germany accounted for the highest number of diagnosed prevalent cases of liver cirrhosis among EU4 and the UK.
  • Japan accounted for approximately 0.5 million cases of the total diagnosed prevalent cases of liver cirrhosis in the 7MM in 2022.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Liver Cirrhosis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from University of Florida Gainesville, Stanford University, Liver Unit, Hospital Clinic of Barcelona, Iwate Medical University, Leipzig University Hospital, and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Liver Cirrhosis, explaining its causes, signs and symptoms, and pathogenesis.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnostic guidelines.
  • The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
  • A detailed review of current challenges in establishing the diagnosis.

Liver Cirrhosis Report Insights

  • Patient Population
  • Country-wise Epidemiology Distribution
  • Total Emergency Visits due to Cocaine

Liver Cirrhosis Report Key Strengths

  • 12 years Forecast
  • The 7MM Coverage
  • Liver Cirrhosis Epidemiology Segmentation

Key Questions

Epidemiology Insights

  • What are the disease risks, burdens, and unmet needs of Liver Cirrhosis? What will be the growth opportunities across the 7MM concerning the patient population of Liver Cirrhosis?
  • What is the historical and forecasted Liver Cirrhosis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
  • Why do only limited patients appear for diagnosis?
  • Which country is more prevalent for Liver Cirrhosis and why?
  • What factors are affecting the diagnosis of the indication?

Reasons to Buy

  • Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the Liver Cirrhosis prevalence cases in varying geographies over the coming years.
  • A detailed overview of Severity, Gender, and Age-specific prevalence of Liver Cirrhosis.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Liver Cirrhosis Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Liver Cirrhosis cases in 2022?

The highest cases of Liver Cirrhosis was found in Germany among EU4 and the UK, in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Liver Cirrhosis cases in 2022?

The highest cases of Liver Cirrhosis were found in the US among the 7MM in 2022.

Table of Contents

1. Key Insight2. Report Introduction
3. Liver Cirrhosis Patient Overview at a Glance
3.1. Patient Share (%) Distribution of Liver Cirrhosis in 2020
3.2. Patient Share (%) Distribution of Liver Cirrhosis in 2034
4. Methodology of Liver Cirrhosis Epidemiology5. Executive Summary of Liver Cirrhosis
6. Disease Background and Overview of Liver Cirrhosis
6.1. Introduction to Liver Cirrhosis
6.2. Etiology of Cirrhosis
6.3. Risk Factors of Liver Cirrhosis
6.4. Multiple Cell Types Contributing to Pathogenesis of Liver Cirrhosis
6.5. Pathogenesis of Liver Cirrhosis
6.6. Stages of Liver Cirrhosis
6.7. Signs and Symptoms
6.8. Complications of Liver Cirrhosis
6.9. Pathophysiology
6.10. Diagnosis of Liver Cirrhosis
6.10.1. Diagnosis Algorithm
6.10.2. Diagnosis Guidelines
6.10.2.1. EASL Clinical Practice Guidelines for the Management of Patients With Decompensated Cirrhosis
6.10.2.2. Evidence-based Clinical Practice Guidelines for Liver Cirrhosis 2020
6.10.2.3. American Association for the Study of Liver Diseases (AASLD) Diagnostic Guidelines for HBV, 2018
6.10.2.4. European Association for the Study of the Liver (EASL) Diagnostic Guidelines for HBV, 2017
6.10.2.5. Diagnostic Guidelines for PBC
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: The 7MM
7.2.1. The United States
7.2.2. EU4 and the UK Countries
7.2.3. Japan
7.3. Total Diagnosed Prevalent Cases of Liver Cirrhosis in the 7MM
7.4. The United States
7.4.1. Total Diagnosed Prevalent Cases of Liver Cirrhosis in the United States
7.4.2. Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in the United States
7.5. Major Five European Countries
7.5.1. Germany
7.5.1.1. Total Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.1.2. Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.2. France
7.5.2.1. Total Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.2.2. Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.3. Italy
7.5.3.1. Total Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.3.2. Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.4. Spain
7.5.4.1. Total Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.4.2. Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.5. The United Kingdom
7.5.5.1. Total Diagnosed Prevalent Cases of Liver Cirrhosis
7.5.5.2. Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis
7.6. Japan
7.6.1. Total Diagnosed Prevalent Cases of Liver Cirrhosis in Japan
7.6.2. Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in Japan
8. Patient Journey9. Key Opinion Leaders’ Views
10. Appendix
10.1. Bibliography
10.2. Acronyms and Abbreviations
10.3. Report Methodology
11. Publisher Capabilities12. Disclaimer
List of Tables
Table 1: Summary of Liver Cirrhosis Epidemiology (2020-2034)
Table 2: Complications of Liver Cirrhosis
Table 3: Common Physical Examination Findings in Patients With Cirrhosis
Table 4: Clinical Laboratory Studies Used in Diagnosing Chronic Liver Disease
Table 5: Level of Evidence and Grade of Recommendations
Table 6: Grading Evidence and Recommendations (Adapted From Grade System)
Table 7: EASL Clinical Practice Guidelines
Table 8: Overview of the Utility of Investigation in PBC
Table 9: Recommendation of EASL
Table 10: The British Society of Gastroenterology/UK Recommendations
Table 11: Total Diagnosed Prevalent Cases of Liver Cirrhosis in the 7MM, in ‘000’ (2020-2034)
Table 12: Total Diagnosed Prevalent Cases of Liver Cirrhosis in the US (2020-2034)
Table 13: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in the US (2020-2034)
Table 14: Total Diagnosed Prevalent Cases of Liver Cirrhosis in the EU4 and the UK (2020-2034)
Table 15: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in Germany (2020-2034)
Table 16: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in France (2020-2034)
Table 17: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in Italy (2020-2034)
Table 18: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in Spain (2020-2034)
Table 19: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in the UK (2020-2034)
Table 20: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in EU4 and the UK (2020-2034)
Table 21: Total Diagnosed Prevalent Cases of Liver Cirrhosis in Japan (2020-2034)
Table 22: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in Japan (2020-2034)
List of Figures
Figure 1: Liver With and Without Cirrhosis
Figure 2: Pathogenesis of Liver Cirrhosis
Figure 3: Stages of Liver Damage
Figure 4: Difference Between Compensated and Decompensated Cirrhosis
Figure 5: Symptoms of Liver Cirrhosis
Figure 6: Complications of Liver Cirrhosis
Figure 7: Pathophysiology of Liver Cirrhosis
Figure 8: Diagnostic Algorithm of Liver Cirrhosis
Figure 9: Total Diagnosed Prevalent Cases of Liver Cirrhosis in the 7MM, in ‘000’ (2020-2034)
Figure 10: Total Diagnosed Prevalent Cases of Liver Cirrhosis in the US (2020-2034)
Figure 11: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in the US (2020-2034)
Figure 12: Total Diagnosed Prevalent Cases of Liver Cirrhosis in the EU4 and the UK (2020-2034)
Figure 13: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in the EU4 and the UK (2020-2034)
Figure 14: Total Diagnosed Prevalent Cases of Liver Cirrhosis in Japan (2020-2034)
Figure 15: Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in Japan (2020-2034)